Trial Profile

A phase I, dose-escalation study of the Eg5-inhibitor EMD534085 in subjects with advanced solid tumors and lymphoma

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 23 Apr 2015

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs EMD 534085 (Primary)
Indications Hodgkin's disease; Non-Hodgkin's lymphoma; Solid tumours
Focus Adverse reactions; First in man
Sponsors Merck KGaA

Most Recent Events

21 Apr 2010 New trial record
17 Apr 2010 Results have been presented at the 101st Annual Meeting of the American Association for Cancer Research.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com